Opus Genetics, Inc. annual report, FY2016

Filing identity and reporting period

Important metadata mismatch: The supplied filing is Rexahn Pharmaceuticals, Inc.’s Form 10-K for the fiscal year ended December 31, 2016—not an Opus Genetics filing. The summary below reflects the filing text provided.

Rexahn was a clinical-stage oncology biopharmaceutical company, with three candidates in Phase II development and one preclinical candidate. It had no approved products or product revenue.

Financial performance and liquidity

With no revenue, conventional revenue margins are not meaningful. FY 2016 net loss improved chiefly alongside lower expenses and substantial noncash warrant fair-value gains; it does not indicate operating profitability. The $5.53 million warrant gain and $1.77 million patent-attorney settlement were included in other income. The filing reports no income-tax provision.

At December 31, 2016, working capital was $19.04 million, total assets $21.04 million, total liabilities $3.99 million and stockholders’ equity $17.06 million. Warrant liabilities were $1.57 million. The supplied text does not identify conventional interest-bearing debt. Rexahn raised $10.12 million net through registered direct offerings in 2016. Common shares outstanding rose from 197.4 million to 237.4 million during the year. Management said available cash and marketable securities should fund current activities for at least 12 months from issuance of the financial statements.

Changes and quarterly context

• Annual net loss narrowed by about $5.08 million versus 2015. R&D expense fell 16.9%, mainly because manufacturing costs declined to approximately $2.56 million from $5.61 million as previously manufactured drug supply remained available; clinical and personnel costs partly offset the reduction.
• G&A expense increased 3.4%, primarily due to personnel costs. Management expected R&D spending to increase in 2017 as enrollment and clinical-trial activity advanced.
• For 2016 Q4, revenue was $0 and net loss was $0.53 million, compared with a $2.85 million net loss in 2015 Q4. Quarterly results were affected by other income, including warrant remeasurement gains.
• Cash and marketable securities decreased about $3.12 million year over year despite positive net cash movement in 2016, reflecting operating cash use and financing and investment flows.

Outlook, developments and risks

• RX-3117 advanced to the second stage of its Phase IIa pancreatic-cancer study after meeting predefined preliminary-efficacy criteria; a Phase IIa advanced bladder-cancer study also began. Management reported preliminary tolerability and efficacy signals, not definitive evidence of benefit.
• Supinoxin completed Phase I enrollment; the filing reports preliminary signs of activity and tolerability. Its Phase IIa triple-negative breast-cancer study began in February 2017, after the fiscal year-end.
• Archexin continued in a Phase IIa renal-cell-carcinoma study with everolimus. The company was not pursuing further development of its Archexin-plus-gemcitabine pancreatic-cancer combination.
• The company was discussing potential collaborations for RX-3117 and Supinoxin, but no new partnership was reported as completed. It lacked internal commercial and manufacturing infrastructure and relied on third parties.
• Key risks include clinical-trial failure or delay, regulatory uncertainty, ongoing losses and need for additional capital, potential dilution from further equity financing, manufacturing and CRO dependence, reimbursement uncertainty, competition, and patent protection. Rexahn disclosed a Japanese patent-filing dispute relating to Supinoxin; it received a $1.77 million settlement in exchange for waiving future claims against the patent attorney, while the patent application remained subject to litigation with the Japanese Patent Office.
• The filing reported no legal proceedings under Item 3, no 2016 share repurchases, and no off-balance-sheet arrangements. Management and the auditor concluded internal control over financial reporting was effective; the financial-statement audit opinion was unqualified.

Most important facts to verify

1. Confirm the intended issuer: the supplied 10-K is for Rexahn Pharmaceuticals, Inc., not Opus Genetics, Inc.
2. Review the original financial statements and notes for cash runway assumptions, the composition and valuation of warrant liabilities, and the noncash warrant gains that materially affected reported losses.
3. Check subsequent filings for clinical-trial enrollment, results, spending, and any collaboration agreements; the clinical signals described here were preliminary.
4. Verify financing needs and dilution exposure, including outstanding warrants and any limits on use of the at-market issuance agreement.
5. Track the Supinoxin Japanese patent litigation and the status and scope of its patent protection.